Gelonghui, January 30, 丨 Tailin Biotech (300813.SZ) announced its 2023 annual results forecast. Net profit attributable to shareholders of listed companies during the reporting period was 18 million yuan to 27 million yuan, down 77.41%-66.12% from the same period last year; net profit profit after deducting non-recurring profit and loss was 11 million yuan to 16.5 million yuan, down 84.87%-77.31% from the same period last year.

During the reporting period, the main reasons for the company's net profit attributable to shareholders of listed companies declined in the same direction as the previous year: 1. During the reporting period, sales revenue of the company's environmental control product line (isolation technology series) and sterilization technology series products declined year-on-year due to factors such as the extension of the inspection cycle required by some customers and the renovation of the subsidiary's relocation to the new park. 2. During the reporting period, the company continued to increase investment in R&D and actively expand research and development of new technologies and products. The company's investment in R&D increased year-on-year. 3. The company actively explores the market. Exhibition and promotion expenses increased year-on-year, and overall period expenses increased compared to the same period last year. 4. During the reporting period, repayments from some customers fell short of expectations, and credit impairment losses calculated in accordance with the company's accounting policies increased significantly compared to the same period last year. Overall, at present, the company's business operations are normal, on-hand orders are stable, cash flow is sufficient, and there have been no major adverse changes in all aspects of production and operation.